Paradigm Capital Management Inc’s Harvard Bioscience HBIO Stock Holding History

Paradigm Capital Management Inc’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-58,190	Closed	-$1.58M	–	172
2016 Q3	$1.58M	Buy	58,190 +9,510	+20%	+$264K	0.17%	85
2016 Q2	$1.39M	Buy	48,680 +14,660	+43%	+$466K	0.17%	96
2016 Q1	$1.03M	Buy	34,020 +11,320	+50%	+$321K	0.12%	115
2015 Q4	$788K	Buy	22,700 +4,231	+23%	+$145K	0.09%	130
2015 Q3	$698K	Buy	18,469 +5,009	+37%	+$233K	0.09%	137
2015 Q2	$767K	Buy	+13,460	New	+$766K	0.08%	140

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Paradigm Capital Management Inc's HBIO Position: Q4 2016 in Review

Paradigm Capital Management Inc sold out of Harvard Bioscience (HBIO) in Q4 2016, closing a stake of 58,190 shares — an estimated $1.58M sold.

Paradigm Capital Management Inc first reported a position in HBIO in Q2 2015 and held it in 6 quarters. The position peaked at $1.58M in Q3 2016. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2016.

Paradigm Capital Management Inc reported no remaining Harvard Bioscience position as of Q4 2016 after selling out during the quarter.
Paradigm Capital Management Inc sold 58,190 Harvard Bioscience shares in Q4 2016, an estimated $1.58M.
Paradigm Capital Management Inc first reported a position in Harvard Bioscience in Q2 2015 and held it in 6 quarters.
Paradigm Capital Management Inc's Harvard Bioscience position peaked at $1.58M in Q3 2016.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2016.

Based on Paradigm Capital Management Inc's 13F filing for Q4 2016, filed 13 Feb 2017.